Stryker Co. (NYSE:SYK) Shares Purchased by Silvercrest Asset Management Group LLC

Silvercrest Asset Management Group LLC grew its holdings in shares of Stryker Co. (NYSE:SYK) by 0.6% during the fourth quarter, Holdings Channel reports. The firm owned 143,957 shares of the medical technology company’s stock after purchasing an additional 872 shares during the quarter. Silvercrest Asset Management Group LLC’s holdings in Stryker were worth $51,832,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of SYK. RTW Investments LP grew its position in shares of Stryker by 48.7% during the fourth quarter. RTW Investments LP now owns 590,221 shares of the medical technology company’s stock worth $212,509,000 after buying an additional 193,300 shares in the last quarter. Rafferty Asset Management LLC raised its position in Stryker by 11.9% in the fourth quarter. Rafferty Asset Management LLC now owns 38,909 shares of the medical technology company’s stock worth $14,009,000 after acquiring an additional 4,134 shares in the last quarter. Raiffeisen Bank International AG purchased a new position in Stryker in the fourth quarter worth $32,189,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Stryker in the fourth quarter valued at $1,836,000. Finally, Redwood Investments LLC grew its holdings in Stryker by 4.7% in the fourth quarter. Redwood Investments LLC now owns 18,433 shares of the medical technology company’s stock valued at $6,637,000 after purchasing an additional 820 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on SYK shares. Barclays raised their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Stifel Nicolaus boosted their price target on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Royal Bank of Canada lifted their price objective on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Needham & Company LLC restated a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Finally, Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $427.05.

Stryker Stock Performance

Shares of NYSE SYK opened at $392.42 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a 50 day moving average price of $366.04 and a 200 day moving average price of $375.15. The stock has a market capitalization of $149.78 billion, a PE ratio of 50.57, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $2.50 EPS. Analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker’s payout ratio is 45.41%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares of the company’s stock, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.